Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR33 vs Insulin Degludec in Type 1 Diabetes
NCT07242664Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of GZR33 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Relative potency of GZR33 to insulin degludec at 2 weeks. Started Oct 2025; status: recruiting.
02
Drugs
GZR33
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07242664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242664.